Associate
Tel: +1 416 616 2144
Email: lmacdonald@tyrllp.com
Professional Designations:
Bar Admission (Ontario), 2017
Practice Areas:
Laura E. MacDonald is a creative and strategic intellectual property litigator with extensive trial experience.
Laura is a senior associate in Tyr LLP's intellectual property litigation group. Laura has experience litigating all types of intellectual property disputes, with a focus on pharmaceutical and complex patent litigation. She regularly represents pharmaceutical companies in patent litigation under the Patented Medicines (Notice of Compliance) Regulations and advises on matters relating to drug price regulation by Canada's Patented Medicines Pricing Review Board (PMPRB). Laura has also represented clients in the chemical, oil and gas, telecommunications, mortgage investment, and health and wellness industries in all types of intellectual property disputes before the Federal Court of Canada and the Federal Court of Appeal. Before joining Tyr LLP, Laura worked in the intellectual property litigation group at McCarthy Tetrault LLP in Toronto.
Laura earned her Juris Doctor (J.D.) cum laude with a specialization in Law and Technology from the University of Ottawa. While in law school, Laura assisted counsel for intellectual property stakeholders in two interventions in the Supreme Court of Canada relating to key issues in patent and copyright law. Laura also achieved an undefeated record in competitive moot court on intellectual property issues. With her team, Laura won the 2015 Harold G. Fox Intellectual Property Moot and the 2016 Oxford International Intellectual Property Moot, and received awards for her advocacy skills at the national and international level. She currently coaches the intellectual property moot teams of a distinguished Canadian law school.
Prior to law school, Laura graduated summa cum laude from McMaster University's Bachelor of Health Sciences Honours program. Her thesis work focussed on disrupting bacterial protein interactions vital to infection to further development of novel treatments for multi-drug resistant infection.
Click on a case to view details.
Allergan Inc. v. Juno Pharmaceuticals Corp. re: LUMIGAN RC® Merck Sharp & Dohme Corp. v. Pharmascience Inc. re: JANUVIA® Bristol-Myers Squibb Canada Co. v. Pharmascience Inc. re: ELIQUIS® Alberta v. Canadian Copyright Licensing Agency (Access Copyright) Bell Canada v. SkyChoice Communications Inc. (T-711-20) Canadian Mortgage Capital Corporation et al. ats Mainstreet Equity Corp. Packers Plus Energy Services Inc. v. Essential Energy Services Ltd.